Posted by Michael Wonder on 07 Sep 2022
Blood cancer patients implore PHARMAC to fund desperately needed medicine
7 September 2022 - New Zealanders living with multiple myeloma are mounting a major, evidence-based campaign to press PHARMAC into funding a transformative treatment that has been standard of care throughout the OECD for more than 5 years.
The treatment patients are desperately calling for is daratumumab, a monoclonal antibody that activates the patient’s immune system to attack and kill cancer cells.
PHARMAC is currently considering funding this.
